Foghorn Therapeutics reports 2026 annual meeting voting results; all proposals pass

Foghorn Therapeutics Inc.

Director nominees elected: Cole (35.1M for, 11.0M against), Gill (46.0M for), Parshall (44.4M for).
Ratification of Deloitte & Touche as auditor for FY2026 approved with 51.7M votes for.
Advisory vote on executive compensation approved with 45.6M for vs 0.5M against.
Stockholders recommended 1-year frequency for future say-on-pay votes (45.6M for one year).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.